Phenex Pharmaceuticals

Gilead Sciences acquires Phenex Pharmaceuticals’ NASH development program

Wednesday, January 7, 2015

Gilead Sciences, a biopharmaceutical company headquartered in Foster City, Calif., and Phenex Pharmaceuticals, a privately held German biotechnology company, have signed a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.

[Read More]

Phenex, Janssen form research collaboration on autoimmune, inflammatory disorders

Monday, December 17, 2012

Phenex Pharmaceuticals, a privately held drug discovery and development company based in Germany, has entered into an agreement with Janssen Biotech and its affiliates to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis and inflammatory bowel disease.

[Read More]